Skip to main content

2018 | OriginalPaper | Buchkapitel

16. Prä-, peri- und postinterventionelle Antikoagulation

verfasst von : PD Dr. med. S. Steiner

Erschienen in: Periphere arterielle Interventionen

Verlag: Springer Berlin Heidelberg

Zusammenfassung

Die antithrombotische Therapie ist ein Eckpfeiler in der Behandlung von Patienten mit symptomatischer pAVK auf Basis atherosklerotischer Gefäßveränderungen. Ziele einer antithrombotischen Therapie bei pAVK umfassen die Reduktion kardiovaskulärer Ereignisse wie Herzinfarkt und Schlaganfall aber auch die Verhinderung einer Progression der pAVK selbst. Basis dieser Dauertherapie sind in erster Linie die Thrombozytenaggregationshemmer Aspirin und Clopidogrel. Wesentlich ist aber auch das antithrombotische Management im Rahmen einer peripheren Intervention, wobei hier in erster Linie Heparine zum Einsatz kommen. Nach endovaskulären Eingriffen stellt sich die Frage der Intensität und Dauer einer Antikoagulation in Abhängigkeit von Lokalisation und Art der peripheren Intervention. Ziel ist es, durch die Senkung von Rezidivereignissen Offenheitsraten und -dauer zu verbessern.
Literatur
Zurück zum Zitat Aboyans et al. (2017) ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2017 Aug 26. doi: 10.1093/eurheartj/ehx095. [Epub ahead of print]CrossRef Aboyans et al. (2017) ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2017 Aug 26. doi: 10.​1093/​eurheartj/​ehx095. [Epub ahead of print]CrossRef
Zurück zum Zitat Alonso-Coello P, et al. (2012) Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e669S–90S Alonso-Coello P, et al. (2012) Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e669S–90S
Zurück zum Zitat Anand SS et al. (2017) Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2017 Nov 10. pii: S0140-6736(17)32409-1. doi: 10.1016/S0140-6736(17) 32409-1. [Epub ahead of print] Anand SS et al. (2017) Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2017 Nov 10. pii: S0140-6736(17)32409-1. doi: 10.​1016/​S0140-6736(17) 32409-1. [Epub ahead of print]
Zurück zum Zitat Antithrombotic Trialists Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329):71–86CrossRefPubMedCentral Antithrombotic Trialists Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329):71–86CrossRefPubMedCentral
Zurück zum Zitat Committee Caprie Steering (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348(9038):1329–39 Committee Caprie Steering (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348(9038):1329–39
Zurück zum Zitat Dake MD, et al. (2011) Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 4(5):495–504 Dake MD, et al. (2011) Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 4(5):495–504
Zurück zum Zitat Dalainas I, et al. (2006) Dual antiplatelet regime versus acetyl-acetic acid for carotid artery stenting. Cardiovascular and interventional radiology 29(4):519–21CrossRefPubMed Dalainas I, et al. (2006) Dual antiplatelet regime versus acetyl-acetic acid for carotid artery stenting. Cardiovascular and interventional radiology 29(4):519–21CrossRefPubMed
Zurück zum Zitat Donovan RJ, et al. (2016) Adjunctive anticoagulation during peripheral vascular intervention. Am Heart J 172:106–14CrossRefPubMed Donovan RJ, et al. (2016) Adjunctive anticoagulation during peripheral vascular intervention. Am Heart J 172:106–14CrossRefPubMed
Zurück zum Zitat Efeovbokhan N, et al. (2014) An objective comparison between bivalirudin and heparin during peripheral vascular interventions. Future cardiology 10(6):717–24CrossRefPubMed Efeovbokhan N, et al. (2014) An objective comparison between bivalirudin and heparin during peripheral vascular interventions. Future cardiology 10(6):717–24CrossRefPubMed
Zurück zum Zitat Eikelboom JW et al. (2017) Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 377:1319–1330 Eikelboom JW et al. (2017) Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 377:1319–1330
Zurück zum Zitat Gerhard-Herman MD, et al. (2016) 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol Gerhard-Herman MD, et al. (2016) 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol
Zurück zum Zitat Hiatt WR, et al. (2017) Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med 376(1):32–40 Hiatt WR, et al. (2017) Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med 376(1):32–40
Zurück zum Zitat Hyhlik-Durr A, et al. (2012) Technical aspects of EVAR for infrarenal AAA. J Cardiovasc Surg (Torino) 53(1 Suppl 1):111–8 Hyhlik-Durr A, et al. (2012) Technical aspects of EVAR for infrarenal AAA. J Cardiovasc Surg (Torino) 53(1 Suppl 1):111–8
Zurück zum Zitat Lip GY, et al. (2014) Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 35(45): 3155–79 Lip GY, et al. (2014) Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 35(45): 3155–79
Zurück zum Zitat McKevitt FM, et al. (2005) The benefits of combined anti-platelet treatment in carotid artery stenting. European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery 29(5):522–7CrossRefPubMed McKevitt FM, et al. (2005) The benefits of combined anti-platelet treatment in carotid artery stenting. European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery 29(5):522–7CrossRefPubMed
Zurück zum Zitat Morrow DA, et al. (2012) Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366(15):1404–13CrossRefPubMed Morrow DA, et al. (2012) Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366(15):1404–13CrossRefPubMed
Zurück zum Zitat Norgren L, et al. (2007) Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 45 Suppl S:S5–67CrossRefPubMed Norgren L, et al. (2007) Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 45 Suppl S:S5–67CrossRefPubMed
Zurück zum Zitat Peeters Weem SMO, et al. (2016) Lack of Evidence for Dual Antiplatelet Therapy after Endovascular Arterial Procedures: A Meta-analysis. European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery 52(2):253–62CrossRefPubMed Peeters Weem SMO, et al. (2016) Lack of Evidence for Dual Antiplatelet Therapy after Endovascular Arterial Procedures: A Meta-analysis. European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery 52(2):253–62CrossRefPubMed
Zurück zum Zitat Rosenfield K, et al. (2015) Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. N Engl J Med 373(2):145–53 Rosenfield K, et al. (2015) Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. N Engl J Med 373(2):145–53
Zurück zum Zitat Tepe G, et al. (2015) Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation 131(5):495–502CrossRefPubMed Tepe G, et al. (2015) Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation 131(5):495–502CrossRefPubMed
Zurück zum Zitat Tepe G, et al. (2012) Management of peripheral arterial interventions with mono or dual antiplatelet therapy – the MIRROR study: a randomised and double-blinded clinical trial. European radiology 22(9):1998–2006CrossRefPubMed Tepe G, et al. (2012) Management of peripheral arterial interventions with mono or dual antiplatelet therapy – the MIRROR study: a randomised and double-blinded clinical trial. European radiology 22(9):1998–2006CrossRefPubMed
Metadaten
Titel
Prä-, peri- und postinterventionelle Antikoagulation
verfasst von
PD Dr. med. S. Steiner
Copyright-Jahr
2018
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-662-55935-2_16

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.